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High-dose chemotherapy followed by autologous hematopoietic cell transplantation (HCT) improves out-
comes in relapsed lymphoma, but the relative efﬁcacy of different preparative regimens is not well deﬁned.
We included patients undergoing autologous HCT using BEAM (carmustine, 300 mg/m2, etoposide, cytar-
abine, and melphalan) or BEP (carmustine 600 mg/m2, etoposide, and cisplatin) between January 2004 and
December 2013; 65 patients received BEP and 64 patients BEAM. Both cohorts were similar for advanced-
stage disease, extranodal and bulky disease, and prior therapies. Median neutrophil and platelet engraft-
ment was 10 and 20 days for both regimens, respectively. Febrile neutropenia, serum creatinine concentration
increase, and electrolyte abnormalities were more frequent with BEP. Incidence of carmustine pneumonitis
was not higher with BEP, likely the result of corticosteroid prophylaxis, although 2 cases of fatal pneumonitis
were observed after BEP. One-year nonrelapse mortality was 6.8% after BEP and 0% after BEAM (P ¼ .379).
After a median follow-up of 39.4 months (range, 1 to 128), 4-year rates of overall survival (OS) after BEP and
BEAM were 80.4% and 72.3%, respectively (P ¼ .611). Diffuse large B cell lymphoma patients transplanted after
early relapse post-rituximab-based ﬁrst-line therapy presented 3-year rates of OS and progression-free
survival (PFS) of 73.8% and 65%, respectively. There were no statistically signiﬁcant differences in the OS
and PFS of follicular lymphoma, mantle cell lymphoma, or Hodgkin lymphoma. BEP is a valid alternative to
BEAM in autologous HCT. Although associated with more renal and electrolytic toxicities, BEP results in
similar disease control and long-term survival as BEAM. Prospective studies are needed to conﬁrm whether
intensiﬁcation of conditioning regimens for autologous HCT can improve disease control in high-risk relapsed
lymphoma patients.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
High-dose chemotherapy supported by autologous
hematopoietic cell transplantation (HCT) has been shown to
result in better progression-free survival (PFS) than con-
ventional salvage chemotherapy for treatment of relapsed
Hodgkin [1] and non-Hodgkin lymphoma patients [2,3].
Although the original studies validating the use ofedgments on page 1931.
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ty for Blood and Marrow Transplantation.autologous HCT were done in the 1990s, more recent studies
continue to demonstrate the utility of this treatment after
the introduction of rituximab [4-8].
Disease status at transplant, sensitivity to salvage
chemotherapy, secondary age-adjusted International Prog-
nostic Index, and timing of recurrence have been identiﬁed
as factors predicting outcome in patients with recurrent
lymphoma [9]. The relative impact of conditioning regimens,
however, is still uncertain [10]. Conditioning regimens
include BEAM (carmustine [BCNU], etoposide, cytarabine,
and melphalan); BCNU, (etoposide, cytarabine, and cyclo-
phosphamide) [11]; CBV (cyclophosphamide, BCNU, etopo-
side) [12]; busulfan, etoposide, and cyclophosphamide [13];
as well as combination regimens with total body irradiation.
Table 1
Baseline Characteristics of Patients Undergoing Autologous HCT with BEAM
and BEP Conditioning
BEAM
(n ¼ 64)
BEP
(n ¼ 65)
P
Male/female 36/28 40/25 .542
Age, yr, median (range) 58 (18-73) 48 (17-72) .078
CCI, median (range) 6 (4-12) 6 (4-24) .233
Diagnoses, n
DLBCL 20 13
Transformed follicular and indolent 6 10
Very aggressive (Burkitt and
lymphoblastic)
0 6
Follicular 6 10
Mantle cell 12 8
T cell 4 5
Hodgkin 16 14
Median number of lines of prior
therapy (range)
2 (1-6) 2 (1-5) .688
Radiation therapy (involved ﬁeld)
before transplant, n
23 14 .119
Disease status before transplant, n .138
CR 51 46
Non-CR 13 18
PET-CT status at the time of transplant, n .678
Negative 42 39
Positive 13 8
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etoposide, and cisplatin (BEP) in this setting [14,15].
Although BEAM and BEP preparative regimens have been
well described, there have been no direct comparisons with
regards to toxicity and efﬁcacy [12,16]. We hereby present a
retrospective analysis of the outcomes of 129 patients
transplanted in our institution during a 10-year period (2004
to 2014) using either of these conditioning regimens.
METHODS
We searched the Stem Cell Transplant Database of the Seidman Cancer
Center of University Hospitals Case Medical Center (Cleveland, OH) for all
lymphoma patients who received an autologous HCT with BEP or BEAM
conditioning between January 2004 and December of 2013. This retro-
spective study was approved by the Institutional Review Board of University
Hospitals Case Medical Center. To avoid biases caused by different patient
follow-up length, the start date for inclusion was the ﬁrst year in which
BEAM conditioning was used in our institution.
Preparative Regimens
All time calculations were based on the day of hematopoietic progenitor
cell reinfusion (day 0). BEP included cisplatin 40 mg/m2 i.v. daily from
days 7 to 3 (total dose 200 mg/m2), BCNU 200 mg/m2 i.v. daily from
days 6 to 4 (total dose 600 mg/m2), and etoposide 800 mg/m2 i.v. daily
from days 6 to 4 (total dose 2400 mg/m2). BEAM consisted of BCNU 300
mg/m2 i.v. on day 6, etoposide 200 mg/m2 i.v. daily from days 5 to 2
(total dose 800 mg/m2), cytarabine 200 mg/m2 i.v. twice daily from days 5
to 2 (total dose 1600 mg/m2), and melphalan 140 mg/m2 i.v. on day 1.
The choice of conditioning regimen was inﬂuenced primarily by the
presence of comorbidities (pulmonary disease, renal dysfunction, peripheral
neuropathy, hearing impairment). Because of the higher doses of BCNU and
etoposide, BEP was preferred for patients not in remission, whereas older
patients were more commonly prescribed BEAM because of concerns of
tolerance. Histologic subtype and prior therapy did not inﬂuence the choice
of regimen.
Pretransplant Radiation Therapy
Involved-ﬁeld radiation therapy, 2000 to 3000 cGy, administered after
hematopoietic cell mobilization to sites of previous bulky disease and to
persistent 18-ﬂuorodeoxyglucose avid lesions after salvage, was prescribed
under the discretion of the treating physician [17].
Supportive and Prophylactic Measures
All patients received prophylaxis against Pneumocystis jiroveci, fungal
infections, and herpesvirus until 100 days after HCT per institutional stan-
dards. All patients received ﬁlgrastim at a dose of 480 mg s.c. starting on the
day of hematopoietic cell infusion until neutrophil engraftment.
The initial studies with BEP conditioning showed high doses of BCNU
were associated with an increased rate of pulmonary toxicity; this toxicity
could be prevented and treated with corticosteroids. Accordingly, all pa-
tients receiving BEP were given prophylaxis with oral prednisone (2 mg/kg
daily) from daysþ7 throughþ14, followed by rapid taper. In addition, forced
diuresis with furosemide (20 mg i.v. 2 minutes before cisplatin) and
mannitol (25 g i.v. in 100 mL dextrose 5% after each dose of cisplatin) were
used to prevent nephrotoxicity.
Statistical Analysis and Deﬁnitions
The date of neutrophil engraftment was deﬁned as the ﬁrst of 3
consecutive days with an absolute neutrophil count above 500/mL, whereas
platelet engraftment was deﬁned as the ﬁrst of 7 days in which a platelet
count above 20,000/mL was documented, without platelet transfusions for a
minimum of 7 days. Overall survival (OS) was measured from the date of
transplant to the date of death or last follow-up for survivors. PFS was
measured from the date of transplant to the date of relapse or death,
whichever occurred ﬁrst.
Cumulative neutrophil and platelet recovery rates were estimated by
the Kaplan-Meier method [18]. Survival duration was compared using the
log-rank test. The predictive value of covariates, including conditioning
regimen and continuous variables (ie, age, comorbidity, number of prior
therapies, CD34þ cell count), on survival was further examined using a Cox
proportional hazard regression model [19]. Cumulative incidence of non-
relapse mortality (NRM) was estimated treating relapse mortality and
relapse as competing risks [20].
Continuous variables were examined using the t-test, whereas the as-
sociation between categorical variables was examined using the chi-square
test or Fisher’s exact test when appropriate. The association betweencontinuous measurements was estimated using Spearman correlation co-
efﬁcient. Linear regressionwas used to identify factors associated with time-
to-discharge, and logistic regression was used to identify the inﬂuence of
covariates on the incidence of transplant-related complications. All tests
were 2-sided, and P  .05 were considered statistically signiﬁcant.
With the exception of pulmonary complications, toxicity analysis
included all complications occurring from the day of transplant through
day þ100. Because pulmonary toxicity can be delayed after BCNU, patients
were monitored for this complication for 1 year after transplant. Infectious
complications included febrile neutropenia, positive cultures, and infections
documented through imaging studies. The occurrence of transplant related
toxicities was identiﬁed through review of the medical records; toxicity
grading was done according to the National Cancer Institute Common
Terminology Criteria for Adverse Events, version 4.03 (http://ctep.cancer.-
gov/protocolDevelopment/adverse_effects.htm; June 14, 2010).
RESULTS
Patient Characteristics
One hundred twenty-nine lymphoma patients under-
went autologous HCT with BEP (n ¼ 65) or BEAM (n ¼ 64)
conditioning between 2004 and 2013. Patient characteristics
are summarized in Table 1. There were no statistically sig-
niﬁcant differences among patients receiving either condi-
tioning regimen, although the median age of BEP patients
was 48 versus 58 years for those treated with BEAM
(P ¼ .078), reﬂecting the preference for BEAM in older pa-
tients. Prior therapy was similar in both groups. Eighty-ﬁve
patients with B cell lymphoma (BEP, n ¼ 43; BEAM, n ¼ 42)
received rituximab at some point before autologous HCT,
and only 10 did not receive this agent in ﬁrst-line therapy.
Sixty-nine patients had prior exposure to platinum agents
(BEP, n ¼ 30, 46.1%; BEAM, n ¼ 39, 60.9%).
Most patients were in complete remission at HCT (BEP
group, n ¼ 46, 70%; BEAM group, n ¼ 51, 83.6%; P ¼ .38).
There was no statistical difference among patients trans-
planted in ﬁrst complete remission (CR) (BEP, n ¼ 16; BEAM,
n ¼ 19), second CR (BEP, n ¼ 20; BEAM, n ¼ 25), or third CR
and beyond (BEP, n¼ 10; BEAM, n¼ 7). A total of 102 patients
underwent imaging with 18-ﬂuorodeoxyglucose positron
emission tomography with computed tomography (PET-CT)
in the 8 weeks preceding HCT (BEP group, n ¼ 47; BEAM
group, n ¼ 55); there was no statistical difference in the
proportion of patients with negative PET-CT at the time of
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P ¼ .34).
Hematopoietic Engraftment
Median time to neutrophil engraftment was 10 days for
both BEP (range, 9 to 16; mean, 10.45) and BEAM (range, 8 to
12; mean, 9.95) conditioning. Age, comorbidity measured by
the Charlson Comorbidity Index (CCI), number of prior
treatment lines, and CD34þ cell dose were not predictive of
neutrophil recovery. Median time to platelet engraftment
was 20 days for both treatment groups, but the cumulative
incidence of platelet counts above 50  109/mL was superior
for BEAM (P ¼ .034). Age, CCI, and number or prior therapy
lines did not inﬂuence platelet engraftment. CD34þ cell dose
correlated signiﬁcantly with time to platelet engraftment:
For every million CD34þ cells/kg infused, the probability of
platelet recovery above 20, 50, and 100 109/mL increased by
7.2%, 7.7%, and 7.3%, respectively (P ¼ .005, .003, and .009,
respectively).
Duration of Hospitalization
Median time from hematopoietic cell infusion to
discharge was 12 days (range, 9 to 23) after BEP versus 12
days (range, 9 to 46) after BEAM (P ¼ .544). Time from
transplant to discharge was inﬂuenced by comorbidities
measured by CCI, with a Spearman correlation coefﬁcient of
.341 (P < .0001). In multivariable regression analysis, there
was no signiﬁcant difference in the time to discharge be-
tween conditioning regimens after controlling for the effects
of gender, age, and CCI.
Toxicities
Table 2 summarizes the incidence of toxicities with each
regimen. Infectious complications included culture-negative
febrile neutropenia, positive blood cultures, or imaging
studies consistent with infection. When grouped together,
infections were more common after BEP (100% versus 87.5%,Table 2
Acute Toxicities* after Autologous HCT with BEP vs. BEAM Conditioning
Regimens
BEAM
(n ¼ 64)
BEP
(n ¼ 65)
P
Infectious complications 56 65 .003
Bacteremia (positive blood cultures) 17 24
Febrile neutropenia 55 63
Renal complications 5 10 .18
Grades 3-4 0 1
Electrolytic abnormalities 55 64 .008
Grades 3-4 42 54
Pulmonary 6 9 .428
Grades 3-4 1 2
Grade 5 0 2
Nausea/vomiting 32 33 .93
Grades 3-4 4 8
Mucositis 28 36 .186
Grades 3-4 13 20
Diarrhea 48 43 .271
Grades 3-4 16 8
Cardiac complications 9 10 .775
Grades 3-4 1 3
Bleeding 7 7 .95
Grades 3-4 1 0
Toxicity data were collected from medical records and graded according to
the Common Terminology Criteria for Adverse Events, version 4.03 (http://
ctep.cancer.gov/protocolDevelopment/adverse_effects.htm; 2010).
* Nonpulmonary toxicities were considered related to autologous HCT if
they occurred up to 100 days after transplant. Pulmonary toxicities include
events observed beyond 100 days after transplant.P ¼ .003). When culture-negative febrile neutropenia was
excluded, the difference did not achieve statistical signiﬁ-
cance (BEP, 60%, versus BEAM, 43.8%; P ¼ .06). There was no
difference in the rate of positive blood cultures (BEP, 36.9%,
versus BEAM, 26.6%; P ¼ .21). The rate of febrile neutropenia
(with or without positive cultures) was higher for BEP (98.5%
versus 85.9%, P ¼ .008). After controlling for the effects of
prior therapy, age, and CCI, the differences in infectious
complications remained statistically signiﬁcant (P ¼ .01).
Multivariable logistic regression showed BEP was asso-
ciated with a higher frequency of serum creatinine elevation
 grade 1 (increase above the upper limit of normal and
above), even after adjusting for the effect of age, number of
prior therapies, and CCI (P ¼ .048). In addition, older age was
predictive of developing increase in creatinine  grade 1,
with each year of age increasing the odds by 7% (P¼ .025). No
patient required hemodialysis.
Electrolyte abnormalities occurring in the ﬁrst 100 days
after transplant were more common after BEP (98.5% versus
85.9%, P ¼ .008). The most common abnormality was hypo-
kalemia, followed by hypomagnesemia and hypopho
sphatemia.
The incidence of other complications was not different
between regimens. Despite the higher dose of BCNU used in
BEP, the incidence of interstitial pneumonitis was similar.
Three patients receiving BEAM (4.7%) and 6 patients treated
with BEP (9.2%) experienced this complication (P ¼ .322),
suggesting corticosteroid prophylaxis after BEP was effective
in preventing pneumonitis in most patients. However, 2
cases of pneumonitis in the BEP cohort were fatal. One of
these patients previously had received mediastinal radiation
immediately before autologous HCT.
Two patients died before 100 days after HCT, both from
the BEP cohort. One patient died 11 days after HCT as a result
of sepsis, whereas 1 death secondary to alveolar hemorrhage
due to pneumonitis occurred 80 days after HCT.
Response and Survival
Disease response was assessed 100 days after HCT in 125
patients. Twopatients in the BEP group did not have response
assessments because of early deaths. Among patients
with measurable disease before transplant (BEP, n ¼ 17;
BEAM, n¼ 13), CR rate was 94%with BEP and 69% after BEAM
(P¼ .07). Overall, 95% and 92% of all patients were in CR after
BEP and BEAM treatment, respectively (P ¼ .718).
There were 12 deaths in the BEP group (18.4%) and 13 in
the BEAM group (20.3%). Causes of death in the BEP group
included sepsis (n ¼ 2), pneumonia (n ¼ 1), alveolar hem-
orrhage (n ¼ 1), chronic interstitial pneumonitis (n ¼ 1),
intestinal obstruction (n ¼ 1), complications of allogeneic
HCT performed for secondary myelodysplastic syndrome
(n ¼ 1), and progressive disease (n ¼ 5). Ten patients in the
BEAM group died from progressive disease, whereas 1 pa-
tient each died of pneumonia, traumatic intracranial hem-
orrhage, and complications of allogeneic HCT for
myelodysplastic syndrome.
After a median follow-up of 39.4 months (range,1 to 128),
4-year rates of OS were 80.4% and 72.3% after BEP and BEAM,
respectively (P ¼ .611) (Figure 1), whereas 4-year rates of PFS
were 71.5% after BEP and 62.4% after BEAM (P ¼ .529)
(Figure 2). Age, gender, disease stage, and the use of
involved-ﬁeld radiation therapy before transplant were not
predictive of OS or PFS. Chemosensitivity, deﬁned as having
achieved at least a partial remission after salvage chemo-
therapy before autologous HCT, was signiﬁcant in predicting
Table 3
Four-Year PFS and OS of Patients after Autologous HCT with BEP vs. BEAM
Conditioning According to Histologic Subtype
4-Year
OS (%)
4-Year
PFS (%)
DLBCL (n ¼ 33)
BEP 69.3 61.4
BEAM 64.2 66.7
P .862 .816
Follicular lymphoma (n ¼ 16)
BEP 88.9 88.9
BEAM 75.0 66.7
P .586 .056
Transformed indolent lymphoma (n ¼ 16)
BEP 100 58.3
BEAM 66.7 66.7
P .144 .957
Mantle cell lymphoma (n ¼ 20)
BEP 100 87.5
BEAM 88.9 73.3
P .378 .756
Hodgkin lymphoma (n ¼ 30)
BEP 81.7 83.3
BEAM 85.7 69.6
P .871 .577
Figure 1. Probability of OS (%) for lymphoma patients after autologous HCT
with BEP (red dashed line) and BEAM (green line) conditioning regimens. (This
ﬁgure is available in color online at www.bbmt.org).
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PFS, .135, P ¼ .01). After controlling for the effects of age,
comorbidity, stage, and chemosensitivity before transplant,
there was no statistically signiﬁcant difference in OS and PFS
between BEP and BEAM groups.
For diffuse large B cell lymphoma (DLBCL) patients, 4-year
rates of OS were 64.2% after BEP and 69.3% after BEAM
(P ¼ .862) and of PFS were 61.4% and 66.7% after BEP and
BEAM, respectively (P ¼ .816). There was no statistical differ-
ence in the cumulative incidence of relapse between treat-
ment groups (P ¼ .99) (Table 3). Twenty DLBCL patients were
transplanted after an early relapse following rituximab-based
ﬁrst-line therapy, with 3-year OS and PFS estimates of 73.8%
(95% conﬁdence interval [CI], 53.9% to 93.7%) and 65% (95% CI,
44.1% to 85.9%). There were no statistically signiﬁcant
differences in the OS and PFS of nontransformed follicular
lymphoma, transformed indolent lymphoma, mantle cell
lymphoma, or Hodgkin lymphoma (Table 3).
The outcomes were also analyzed according to PET-CT
status before HCT. Four-year rates of OS were 83.3% and
52.4% for PET-negative and PET-positive patients, respec-
tively (P ¼ .02; HR, .379; 95% CI, .098 to .866) (Figure 3A).
Four-year rates of PFS were 82.7% for PET-negative patients
and 48.1% for PET-positive patients (P < .001; HR, .242; 95%
CI, .041 to .385) (Figure 3B). For PET-negative patients, both
conditioning regimens resulted in similar outcomes: 4-year
rates of OS were 88.5% after BEP and 86% after BEAMFigure 2. Probability of PFS (%) for lymphoma patients after autologous HCT
with BEP (red dashed line) and BEAM (green line) conditioning regimens. (This
ﬁgure is available in color online at www.bbmt.org).(P ¼ .796) and of PFS 83.9% after BEP and 83% after BEAM
(P ¼ .684). The outcomes of PET-positive patients were more
disparate between conditioning regimens, but the difference
was not statistically signiﬁcant because of the small number
of patients, with 4-year rates of OS of 68.6% after BEP and
46.2% after BEAM (P ¼ .542) and PFS of 66.7% and 38.5% after
BEP and BEAM, respectively (P ¼ .205).
DISCUSSION
More than 2 decades have elapsed since the use of
autologous HCT was demonstrated to be an effective salvage
therapy for recurrent lymphoma [1,2]. Although the Collab-
orative Trial in Relapsed Aggressive Lymphoma (CORAL) trial
suggested prior rituximab exposure was associated with
worse outcomes after autologous HCT [21], subsequent
studies, including a report by the European Blood and
Marrow Transplantation Registry [22], demonstrated that
this modality continues to provide disease-free survival
beneﬁt in the rituximab era.
The BEP regimen, developed and validated through
studies done at the Case Comprehensive Cancer Center, is
more intense than BEAM, with 2 times the dose of BCNU and
a higher dose of etoposide in addition to cisplatin [14,15].
There are no prospective studies comparing conditioning
regimens to date. A few retrospective studies comparing CBV
and BEAM [10,12,23] have reported improved outcomes and
decreased toxicity with BEAM. However, the compared co-
horts were not concurrent, and improvements in supportive
care, patient selection, and salvage regimens most likely
positively affect the outcomes of the more recently used
BEAM regimen [10]. In our study we examined patients
treated within the same 10-year period, with the only dif-
ference in supportive care consisting of the use of cortico-
steroid prophylaxis in the BEP group. Over the past decade,
our clinical pathways for lymphoid malignancies have
allowed the use of either BEAM or BEP, with selection based
on the expected tolerance of patients of each regimen.
In the CORAL study, early relapse (<12 months after
diagnosis), elevated age-adjusted International Prognostic
Index, and prior rituximab treatment affected the response to
salvage therapy, event-free survival, PFS, and OS in DLBCL
[21]. Early relapse and prior rituximab deﬁned a poor-risk
Figure 3. (A) Probability of OS (%) for lymphoma patients after autologous HCT for patients with PET-CTenegative (green line) and PET-CTepositive (red dashed line)
status before transplant. (B) Probability of PFS (%) for lymphoma patients after autologous HCT for patients with PET-CTenegative (green line) and PET-CTepositive
(red dashed line) status before transplant. (This ﬁgure is available in color online at www.bbmt.org).
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responding and proceeding to transplant having better out-
comes, a 3-year PFS rate of 39%. In our study, the same pop-
ulationpresented 3-year rates of OS and PFS of 73.8% and 65%,
respectively. When the effect of conditioning regimen was
compared in this subgroup of patients, the outcomes were
less balanced, with 3-year OS rates of 80% after BEP and 56%
after BEAM(P¼ .180) and3-year PFS rates of 80% after BEP and
50% after BEAM (P¼ .132). There were no cases of NRM in the
BEP-treated DLBCL group, suggesting the competing risk of
NRM did not inﬂuence this difference in PFS. Although these
data come from a small subgroup analysis, they suggest a
more intensive conditioning regimen such as BEP may be of
beneﬁt and should be studied prospectively in high-risk
DLBCL patients. These results are in line with observations
of improved outcomes in DLBCL with regimens more intense
than rituximab, cyclophosphamide, doxorubicin, vincristine
and prednisone (R-CHOP) [24] and with other intense con-
ditioning regimens for HCT [25].
Several reports have demonstrated the value of PET-CT
performed before autologous HCT for non-Hodgkin and
Hodgkin lymphoma [26,27]. Our results align with these
ﬁndings, and patients with positive PET imaging before
transplant had signiﬁcantly worse OS and PFS. Although
outcomes were very similar among conditioning regimens
for patients with negative PET imaging before transplant,
BEP conditioning may have beneﬁted patients with positive
PET imaging, suggesting again that high-risk patients may
beneﬁt most from dose intensiﬁcation before autologous
HCT. However, the subgroup of PET-positive patients was too
small to determine whether the difference in PFS observed
between conditioning regimens was statistically signiﬁcant.
Along with the observations in high-risk DLBCL subjects,
these data highlight the need for studies to determine
whether more intense conditioning regimens can improve
the outcomes of patients with high-risk disease undergoing
autologous HCT.
Certain toxicities were more frequent with the more
intense BEP regimen, speciﬁcally the risk of infections, serum
creatinine elevation, and electrolyte wasting. The increase in
infectious complications was driven by the higher rate of
febrile neutropenia, but infections with demonstrable site or
positive blood cultures were not different. The higher rate of
electrolytic abnormalities and elevations of serum creatinine
was most likely secondary to the use of high doses of
cisplatin. Despite these higher toxicities, there was no
statistically signiﬁcant difference in 30-day mortality orduration of hospitalization, suggesting the overall impact of
differences on the transplant hospitalizationwas limited. It is
possible that a higher rate of febrile neutropenia would
result in higher costs of hospitalization, although this anal-
ysis was beyond the scope of this study.
A recent report from the Center for International Blood
and Marrow Transplant Research comparing conditioning
regimens in autologous HCT for lymphoma found that 1-year
NRM was 4% after BEAM, 7% for CBV containing low-dose
BCNU (median 300 mg/m2), and 8% for CBV containing
high-dose BCNU (median 450 mg/m2) [28]. One-year NRM
after BEP conditioning (6.1%) was comparable with that
observed after CBV regimens in populations comparable in
age. It is possible that our selection of younger patients
without renal comorbidities led to underestimation of the
NRM rates, although there was no statistically signiﬁcant
difference between BEP and BEAM in the degree of comor-
bidity asmeasured by the CCI. Nevertheless, it is important to
highlight that the 1-year NRM rate in BEAM was 0%, sug-
gesting that conditioning regimen is better tolerated and can
be used safely in older populations. BEP has not been asso-
ciated so far with an increased risk of therapy-related
myeloid malignancies, with only 1 subject experiencing
high-risk myelodysplastic syndrome in each cohort; there-
fore, continued monitoring is necessary.
OS was almost identical after both regimens, with 4-year
OS rates of 80.4% and 72.3% for BEP and BEAM, respectively.
Although these outcomes appear to be excellent when
compared with survival rates after transplant for relapsed
DLBCL [2,21,22], they are most likely improved by the in-
clusion of subjects with Hodgkin lymphoma and indolent
non-Hodgkin lymphoma.
This retrospective study has several limitations. First, the
inclusion of different lymphoma subtypes impedes drawing
deﬁnitive conclusions regarding disease control and survival.
However, the excellent outcomes without over-
representation of indolent lymphomas suggest long-term
survival was excellent across all subtypes. Longer follow-up
and larger numbers of patients are necessary to determine
if any speciﬁc lymphoma subtype or disease status beneﬁts
speciﬁcally from the more intense BEP conditioning. Second,
the median age difference between groups approached sta-
tistical signiﬁcance, possibly a result of the selection of
younger patients for the BEP regimen. Treating physicians
were allowed to select between BEP and BEAM based on
expected tolerance, and this could have led to the introduc-
tion of uncontrolled bias. It is possible that the lower median
P.F. Caimi et al. / Biol Blood Marrow Transplant 21 (2015) 1926e1931 1931age of BEP-treated patients is an effect of such bias. However,
our analysis did not indicate a difference in comorbidity as
measured by the CCI or an effect in OS or PFS from either age
or comorbidity. Older agewas associated with higher rates of
renal toxicity with either regimen but conﬁrms that more
intense regimens such as BEP are more appropriate for
younger patients with higher functional reserve.
In conclusion, BEP is an intense conditioning regimen for
autologous HCT, with short- and long-term outcomes com-
parable with those of BEAM. The increased intensity results
in a higher likelihood acute toxicities but with limited clinical
impact. High-risk relapsed lymphoma patients may present
better outcomes with intensive conditioning regimens, and
larger, prospective studies are necessary to validate this
therapeutic strategy.
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